Aptamer-hybrid nanoparticle bioconjugate efficiently delivers miRNA-29b to non-small-cell lung cancer cells and inhibits growth by downregulating essential oncoproteins
Maryna Perepelyuk, Christina Maher, Ashakumary Lakshmikuttyamma, Sunday A Shoyele Department of Pharmaceutical Science, College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, USA Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. However, their ther...
Guardado en:
Autores principales: | Perepelyuk M, Maher C, Lakshmikuttyamma A, Shoyele SA |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2e56db46bd7c4fd595fce7573e714264 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expression of AIF, PARP, and miRNAs MIR-145, MIR-210, and MIR-486 Associated with Apoptosis in the Corpus Cavernosum Of Rats Subjected to Chronic Alcoholism Model
por: Sarraipo,Vagner Schiavoni, et al.
Publicado: (2020) -
MicroRNA-27b Expression in Rats Submitted to Physical Exercise and Experimental Cerebral Ischemia
por: De-Russi,Brenno Marco, et al.
Publicado: (2021) -
Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy
por: Do-Hun Kim, et al.
Publicado: (2021) -
An Aptamer-Based Biosensor for the Azole Class of Antifungal Drugs
por: Gregory R. Wiedman, et al.
Publicado: (2017) -
Assessment of Cell-Free Long Non-Coding RNA-H19 and miRNA-29a, miRNA-29b Expression and Severity of Diabetes
por: Alfaifi M, et al.
Publicado: (2020)